Key result
LDL-C ≤0.78 mmol/L is not linked to increased bleeding in ACS patients on PCSK9i and DAPT.
Why the study?
The safety of achieving ultra-low LDL-C levels in ACS patients on DAPT, particularly regarding global coagulability, platelet reactivity, and bleeding risk, required further validation.
Does achieving an LDL-C level ≤0.78 mmol/L increase bleeding risk or alter coagulability in post-PCI ACS patients receiving PCSK9 inhibitors and DAPT?
Cohort (n=120)
Open-label
No
Does achieving an LDL-C level ≤0.78 mmol/L increase bleeding risk or alter coagulability in post-PCI ACS patients receiving PCSK9 inhibitors and DAPT?
Achieving ultra-low LDL-C levels (≤0.78 mmol/L) with PCSK9 inhibitors in post-PCI ACS patients on DAPT does not appear to increase bleeding risk or alter platelet reactivity, supporting the safety of profound lipid-lowering.
Answers are grounded in this paper and cite their sources.
No increased bleeding risk observed with ultra-low LDL-C on PCSK9 inhibitors plus DAPT; hypothesis-generating for safety in ACS and requires RCT validation.
Background The safety of achieving ultra-low low-density lipoprotein cholesterol (LDL-C) levels in acute coronary syndrome (ACS) patients on dual antiplatelet therapy (DAPT), particularly regarding global coagulability, specific platelet reactivity, and bleeding risk, requires further validation. Methods In this prospective, open-label, single-center cohort study, 120 post-PCI ACS patients treated with PCSK9 inhibitors and DAPT were enrolled. After a 2-week run-in, patients were stratified by their achieved LDL-C levels into a Low LDL-C group (≤0.78 mmol/L) and a Non-Low LDL-C group (>0.78 mmol/L). Global coagulability and specific platelet reactivity were serially assessed via thromboelastography and rapid platelet function assays over 12 months. The primary safety endpoint was clinically relevant bleeding [Bleeding Academic Research Consortium (BARC) types 2, 3, or 5]. Results The incidence of clinically relevant bleeding was comparable between the Low LDL-C (6.7%) and Non-Low LDL-C (5.0%) groups (risk difference 1.7%, 95% CI: −5.8% to 9.2%). Due to the sparse number of overall bleeding events ( n = 7), the pre-specified non-inferiority analysis was severely underpowered; therefore, these safety findings are reported descriptively. Exploratory time-to-event analysis showed no significant difference in overall bleeding risk (log-rank P = 0.72). Global coagulability and specific platelet reactivity parameters remained stable throughout follow-up, with no significant intergroup differences (all P > 0.05). Major adverse cardiovascular events (MACE) occurred in 6.7% of the Low LDL-C group and 13.3% of the Non-Low LDL-C group (HR 0.48, 95% CI: 0.15–1.55; log-rank P = 0.22). Conclusion In ACS patients receiving PCSK9 inhibitors and DAPT, achieving an LDL-C level ≤0.78 mmol/L was associated with neither an increased bleeding risk nor significant alterations in global coagulability and specific platelet reactivity. These exploratory observational findings descriptively support the clinical safety of profound lipid-lowering in this high-risk population.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2026) conducted a cohort in Acute coronary syndrome (ACS) post-PCI (n=120). Achieved Low LDL-C (≤ 0.78 mmol/L) vs. Non-Low LDL-C (>0.78 mmol/L) was evaluated on Clinically relevant bleeding (BARC types 2, 3, or 5) (Risk difference 1.7%, 95% CI -6.7% to 10.0%, p=0.72). Achieving an LDL-C level ≤ 0.78 mmol/L in ACS patients on PCSK9 inhibitors and DAPT did not increase the risk of clinically relevant bleeding compared to higher LDL-C levels.
Synapse has enriched 10 related papers. Consider them for comparative context: